Solvay Cilansetron NDA "Not Approvable" For Irritable Bowel Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
The "not approvable" letter requests additional clinical trials as well as changes to some non-clinical items, Solvay says. The company says it has informed FDA of its intent to amend the application.